KELOWNA, British Columbia - Lexaria Bioscience (NASDAQ:LEXX) Corp. (NASDAQ: LEXX & LEXXW), a company specializing in drug delivery platforms, has shared interim results from its ongoing animal study, indicating potential benefits in diabetes management. The study, identified as WEIGHT-A24-1, reported reductions in blood sugar levels with the use of its DehydraTECH technology.
The findings at day 56 showed that DehydraTECH-liraglutide and two DehydraTECH-CBD formulations were the top performers, with reductions in blood sugar levels of 2.50%, 1.90%, and 1.53% respectively. These results suggest that DehydraTECH-CBD could be particularly useful when used in conjunction with a GLP-1 drug for controlling diabetes. The study is still in progress, with further results anticipated shortly.
In comparison to a previous study, DIAB-A22-1, where untreated obese control group animals saw a 16.7% increase in blood sugar concentration by day 56, the current study's active groups either experienced a smaller increase or an actual decrease. Notably, animals receiving semaglutide did not show decreases at day 56, although some were observed at day 28.
The continued relative success of DehydraTECH liraglutide is noteworthy, especially given that in other human studies, semaglutide typically outperforms liraglutide in blood sugar control when not processed with DehydraTECH. Liraglutide, a drug owned by Novo Nordisk (NYSE:NVO) and sold under the brand names Victoza and Saxenda, generated $1.6 billion in revenue in 2022 and is currently only available as an injectable.
Lexaria's patented DehydraTECH platform is designed to enhance the delivery of active pharmaceutical ingredients (APIs) through oral routes. The company has been investigating this technology since 2016 and has secured 46 patents with more pending globally.
Study WEIGHT-A24-1 is using diabetic Zucker rats and will collect over 1,500 blood samples for detailed analyses. The study will also observe body weight, blood glucose levels, and conduct a comprehensive set of liver and kidney function tests.
The press release includes forward-looking statements regarding the company's research initiatives and the potential effects of its studies. However, these statements are subject to various risks and uncertainties, and there can be no assurance that the company will achieve the disclosed plans or expectations.
This report is based on a press release statement and aims to provide a factual overview of Lexaria Bioscience Corp.'s ongoing research without endorsing the claims or potential of the technology.
In other recent news, Lexaria Bioscience has announced positive outcomes from a joint research program with the National Research Council of Canada, focusing on the DehydraTECH technology's effectiveness in processing the GLP-1 drug, semaglutide. The study indicated that semaglutide maintained its monomeric form when released into a simulated gastric fluid, a crucial factor for efficient drug absorption. This aligns with the behavior of Rybelsus®, a commercially available version of the drug.
The study also showed promising interim results in a diabetes treatment study using diabetic pre-conditioned Zucker rats. The rats reported decreased weight gain and, in some cases, weight loss. The firm H.C. Wainwright has maintained its Buy rating for Lexaria Bioscience, highlighting the potential of the DehydraTECH technology to significantly impact obesity and diabetes treatment.
Lexaria Bioscience has also expanded its management team, appointing Nelson Cabatuan as the consulting Chief Strategic Financial Advisor. The company has been focusing on expanding its research and development activities, with plans for additional research projects centered on glucagon-like peptide-1 (GLP-1) molecules. Additionally, Lexaria Bioscience has expanded its intellectual property portfolio with the acquisition of two significant patents pertaining to the treatment of hypertension and epilepsy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.